Právní předpis byl sestaven k datu 25.07.2019.
Zobrazené znění právního předpisu je účinné od 04.01.2018 do 25.07.2019.
80
SDĚLENÍ
Ministerstva xxxxxxxxxxxx věcí,
kterým xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. x. x x. 46/2008 Xx. x. x.
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 28. xxxxxxxxx 2016 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx znění Xxxxxxx X (Xxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx xxx xxx 2017 - Xxxxxxxxxxx xxxxxxxx) Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx1).
X novým xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx České xxxxxxxxx a prezident xxxxxxxxx podepsal xxxxxxx x xxxxxxx xxxx Xxxxxxx X Českou xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x souladu x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2017 x pro Českou xxxxxxxxx vstoupilo x xxxxxxxx dne 30. xxxxx 2017.
Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X x platnost xxxxxxxx xxxxxx xxxxx Xxxxxxx I xxxxxx xx 1. ledna 2016, xxxxxxxxx xxx č. 26/2017 Sb. m. s.
Xxxxxxxx znění Přílohy X x xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
XXXXXXX ANTIDOPINGOVÝ XXXXX
XXXXXX XXXXXXXXXX XXXXX A XXXXX XXXXXXX XXX XXX 2017
MEZINÁRODNÍ XXXXXXXX
Xxxxxxxxx xxxx Xxxxxxx xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx.
X xxxxxxx jakýchkoliv xxxxxxxxx xxxx anglickou a xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx anglická xxxxx.
Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2017
XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX ROK 2017
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx od 1. xxxxx 2017
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin S1, X2, X4.4, S4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 a X3.
XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ) |
ZAKÁZANÉ LÁTKY
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx farmakologicky xxxxxx látka, xxxxx xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Seznamu x není aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx látky xxxx xxxxxxxx.
1. ANABOLICKÉ XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);
xxxxxxxxx (estr-4-en-3ß, 17ß-xxxx);
xxxxxxxxxx;
xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);
dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);
xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);
xxxxxxxxxxx;
xxxxxxxxxxxxx (19-norpregna-4-en-17α-ol);
fluoxymesteron;
formebolon;
furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);
xxxxxxxxx;
4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);
xxxxxxxxxx;
xxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);
metenolon;
methandriol;
metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);
xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);
xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);
xxxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestr-4-en-3-on);
methyItestosteron;
metribolon (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);
xxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxxxxx;
xxxxxxxxxxxx;
xxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);
xxxxxxxxx;
xxxxxxxxxx;
xxxxxxxxx;
1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);
xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);
x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
x. Xxxxxxxxx** AAS, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);
xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);
xxxxxxxx;
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);
xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx);
xxxxxxxxx (19-xxxxxxxxxxxxxx);
19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);
19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);
testosteron;
a xxxxxx xxxxxxxxxx x isomery, xxx ne x xxxxxxxx xxxxx na xx:
5α-xxxxxxxxx-3α,17α-xxxx;
5α-xxxxxxxxx-3α,17ß-xxxx;
5α-xxxxxxxxx-3ß,17α-xxxx;
5α-xxxxxxxxx-3ß,17ß-xxxx;
5ß-xxxxxxxxx-3α,17ß-xxxx;
5α-xxxxxxx-2-xx-17-xx;
xxxxxxx-4-xx-3α,17α-xxxx;
xxxxxxx-4-xx-3α,17ß-xxxx;
xxxxxxx-4-xx-3ß,17α-xxxx;
xxxxxxx-5-xx-3α,17α-xxxx;
xxxxxxx-5-xx-3α,17ß-xxxx;
xxxxxxx-5-xx-3ß,17α-xxxx;
4-xxxxxxxxxxxxx (androst-4-en-3ß,17ß-diol);
5-androstendion (xxxxxxx-5-xx-3,17-xxxx);
xxxxxxxxxxx;
xxx-xxxxxxxxxxxxxxxxxx;
xxxxxxxxxxxxxx;
xxxxxxxxxxxxxx;
3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;
7α-xxxxxxx-XXXX;
7ß-xxxxxxx-XXXX;
7-xxxx-XXXX;
19-xxxxxxxxxxxxxx;
19-xxxxxxxxxxxxxxxxx.
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx; selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX, xxxx. xxxxxxx a xxxxxxx); tibolon; xxxxxxx x xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx k látce, xxxxxx xxxx normálně xxxxxxxxx neprodukuje. ** "endogenní " xx vztahuje x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx. |
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX A XXXXXXXX
Xxxxxxxxxxx xxxxx a další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:
1. Agonisté xxxxxxxxxxxxxxxxx receptoru:
1.1 Látky xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx xxxx.
xxxxxxxxxxxx (dEPO);
erytropoetinů (XXX);
XXX-Xx;
XXX-xxxxxxxxxxx peptidů (XXX), xxxx. XXXX 530 x xxxxxxxxxxx;
xxxxxxxxxx GATA, xxxx. X-11706;
xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX);
xxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-xxxx), xxxx. xxxxxxxxxxx, xxxxxxxxxxxx;
1.2 Xxxxxxxx neerytropoetického XXX xxxxxxxxx, xxxx.
XXX-290;
xxxxxx XXX;
xxxxxxxxxxxxx XXX;
2. Xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx, xxxxxxxxxx x xxxxxxxxxx (FG-4592); x aktivátory XXX, xxxx. xxxxx x xxxxx.
3. Xxxxxxxxxxxxxxxxxx (XX) x luteinizační xxxxxx (XX) a jejich xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx, x xxxx.
4. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxxxxx.
5. Xxxxxxx hormon (XX) a xxxx xxxxxxxxxx faktory xxxxxx: xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1295, sermorelinu a xxxxxxxxxxxx; sekretagogů xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxxx x xxxxxxx xxxxxxxx, např. xxxxxxxxxxx x ipamorelinu; xxxxxxxxxxxx xxxxxxx růstového xxxxxxx (XXXX), xxxx. xxxxxxxxxxxxx, XXXX-6, xxxxxxxxxx x xxxxxxxxxxxx (GHRP- 2).
Kromě xxxx xxxx zakázány xxxxxxxxxxx xxxxxxx xxxxxxx:
Xxxxxxxxxxxxx xxxxxxx faktory (FGFs); xxxxxxxxxxxx xxxxxxx xxxxxx (XXX); insulinu xxxxxxx xxxxxxx xxxxxx-1 (IGF-1) x xxxx xxxxxxx; xxxxxxxxxx xxxxxxx faktory (XXX); růstový xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx nebo xxxxxxxxx xxxxxxxx svalů, xxxxx x xxxxxx, xxxxxx zásobení, využití xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta2- xxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.
Xxxxxxxx (xxx ne x xxxxxxxx xxxxx xx xx):
Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxx.
Xxxxxxxx xxxx:
- xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx, xxxxxxxxxxx 800 xxxxxxxxxx za každých 12 xxxxx;
- xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů za 24 xxxxx;
- xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.
Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx abnormální xxxxxxxx xxx xxxxxxxx užíváním xxxxxxxxxxxx dávky (v xxxxxxxx) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx;
xxxxxxxxxx;
xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);
xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);
4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);
xxxxxxxxx;
xxxxxxxxx;
xxxxxxxx;
xxxxxxxxxxx,
xxx ne x omezením pouze xx ně.
2. Selektivní xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), zahrnující:
Raloxifen;
xxxxxxxxx;
xxxxxxxxx, xxx ne x xxxxxxxx xxxxx na xx.
3. Ostatní antiestrogenní xxxxx xxxxxxxxxx:
Xxxxxxxxxx; xxxxxxxxxxx x xxxxxxxx, ale xx x omezením xxxxx na ně.
4. Xxxxx modifikující funkci(e) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx
x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX; x Xxxxxxxx Receptoru xxxxx xxxxxxxxxxxx peroxizomovými xxxxxxxxxxxxx (XXXXδ), např. XX 1516;
5.2 Xxxxxxxx x mimetika insulinů;
5.3 Xxxxxxxxx;
5.4 Xxxxxxxxxxxx.
X5. DIURETIKA X XXXXXXXXX LÁTKY
Následující xxxxxxxxx x xxxxxxxxx xxxxx xxxx xxxxxxxx, xxxxxx jako xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou a xxxxxxxxx xxxxxxxxxxxx xxxxxx.
Xxxxxxxx:
-
Xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání albuminu, xxxxxxxx, hydroxyethylškrobu a xxxxxxxxx), xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
-
Acetazolamid, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, kanrenon, xxxxxxxx xxxxxxxxxx, metolazon, xxxxxxxxxxxxx, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, chlorothiazid), xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx na xx.
X xxxxxxxx:
-
xxxxxxxxxxxx, xxxxxxxxx a xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x brinzolamidu)
-
Lokálního xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx
Xxxxx jakéhokoliv xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo
případně Xxx Soutěži xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx, bude xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Terapeutickou xxxxxxx (XX) xx xxxx látku xxxxx x xx, xxxxx xxx byla xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXXX S XXXX A XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxx znovuzavedení xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx krvinek x xxx podobných produktů xxxxxxxxxxx xxxxxx do xxxxxxxxx systému.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky kyslíku.
Zahrnující:
modifikované xxxxxxxxxxxxx produkty (např. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu a xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx není.
3. Xxxxxxxxx forma intravaskulární xxxxxxxxxx x krví xxxx x krevními xxxxxxxxxxxx fyzikálními nebo xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X FYZIKÁLNÍ MANIPULACE
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx integritu x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole. Xx zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx xx x omezením xxxxx xx ně.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
X3. XXXXXX DOPING
Z xxxxxx potenciálu xx xxxxxxx sportovního xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;
2. Xxxxxxx normálních xxxx geneticky xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX XXXXXXXX XXX SOUTĚŽI |
Kromě xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx
xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx případných optických xxxxxxx, xxxx. x- x X-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/,
xxxxxxxxxx,
xxxxxxxxxxx,
xxxxxx,
xxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxxx (x-),
xxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxxxxx,
x-xxxxxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, je Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx.
Xxxxxxxx (ale ne x omezením pouze xx xx):
Xxxxxxxxx (xxxxxxxxx)****,
xxxxxxxxxxx,
xxxxxxxxxxxxxxxxx,
xxxxxxx***,
xxxxxxxx,
xxxxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxx x jeho xxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx),
xxxxxxxxxxxx,
xxxxx**,
xxxxxxx x jeho xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx a xxxx-xxxxxxxxxxxxxxxxxxxxx),
xxxxxxxxxxxxxxx,
xxxxxxxxxxxx,
xxxxxxxxxxxx***,
xxxxxxxxxxxxxxxxxxxxxxxx,
xxxxxxxxxxxx,
4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxx (metylsynefrin),
pemolin,
pentetrazol,
propylhexedrin,
pseudoefedrin*****,
selegilin,
sibutramin,
strychnin,
tenamfetamin (metylendioxyamfetamin),
tuaminoheptan
a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
X xxxxxxxx:
-
xxxxxxxxx
-
xxxxxxxx xxxxxxxxx x xxxxxxx jejich xxxxxxxx/xxxxxx použití x xxxxxxxxxxx zahrnutých do Xxxxxxxxxxxxxx programu xxx xxx 2017*.
* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: Tyto xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2017 x nejsou považovány xx Xxxxxxxx xxxxx.
** Xxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx moči.
*** Xxxxxxx x xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.
**** Adrenalin (xxxxxxxxx): xxxx zakázán xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx xxxx jeho xxxxxx společně x xxxxxxxxx anestetiky.
***** Pseudoefedrin: xx xxxxxxx, xxxxx xxxx koncentrace x xxxx je xxxxx xxx 150 mikrogramů xx mililitr.
S7. XXXXXXXXX
Xxxxxxxx xx následující:
Buprenorfin,
dextromoramid,
diamorfin(heroin),
fentanyl a xxxx deriváty,
hydromorfon,
metadon,
morfin,
nikomorfin,
oxykodon,
oxymorfon,
pentazocin,
petidin.
S8. XXXXXXXXXXX
Xxxxxxxx xx následující:
-
Přírodní (xxxx. xxxxx, konopí x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX).
-
Xxxxxxxxxxxxxx, xxxx. "Xxxxx", XXX018, XXX073 x XX-210.
X9. XXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX |
X1. ALKOHOL
Alkohol (xxxxxx) xx xxxxxxxx pouze Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0,10 x/x.
-
Xxxxxxxxxxxx xxxxx (XXX)
-
Xxxxxxxxxxx (XX)
-
Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)
-
Xxxxx motorismus (XXX)
X2. BETA-BLOKÁTORY
Beta-blokátory jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx, x xxx xx xx xxxxxxxx x Xxxx soutěž.
-
Automobilový xxxxx (XXX)
-
Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
-
Xxxx (XXX)
-
Xxxxxxxxxxx (XX)*
-
Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x U-rampa, x xxxxxxxxx X-xxxxx x "xxx air"
-
Podvodní sporty (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx konstantní xxxx x xxxxxxxxx xxxx bez xxxxxxx, xxxxxxxxx xxxxx s xxxxxxxxx nebo bez xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, spearfishing, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx xxxx x xxxxxxxxxx xxxx.
-
Xxxxxxx (XXXX, IPC)*
-
Šipky (WDF)
* Xxxxxxxx xxxx Xxxx xxxxxx
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Xxxxxxxxxx,
xxxxxxxxxx,
xxxxxxxx,
xxxxxxxxx,
xxxxxxxxxx,
xxxxxxx,
xxxxxxxxxx,
xxxxxxx,
xxxxxxxxx,
xxxxxxxxxx,
xxxxxxxxx,
xxxxxxxxxxx,
xxxxxxxxxxxx,
xxxxxxxxxx,
xxxxxxx,
xxxxxxxxxx,
xxxxxxxx,
xxxxxxxxxxx,
xxxxxxx,
xxxxxxx,
xxx xx x xxxxxxxx xxxxx na xx.
Informace
Právní xxxxxxx č. 80/2017 Xx. m. x. xxxxx xxxxxxxxx xxxx 4.1.2018.
Právní xxxxxxx x. 80/2017 Sb. x. s. byl xxxxxx xxxxxxx předpisem č. 36/2019 Sb. m. s. x xxxxxxxxx xx 26.7.2019.
Znění jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.
1) Mezinárodní xxxxxx xxxxx xxxxxxx ve xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx, byla xxxxxxxxx x anglickém xxxxx x x xxxxxxxxx do xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.
Nové xxxxx xxxxxxxx Xxxxxx xx xxxxxxx jazyka xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.